Earnings ·
NeOnc Technologies Holdings, Inc. reported second quarter 2026 financial results and announced that topline data from…
NTHINeonc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. reported second quarter 2026 financial results and announced that topline data from its fully enrolled Phase 2a NEO100 study will be presented on August 12, 2026. The company incurred a net loss of $14.2 million, or $(0.58) per diluted share, compared to a $5.7 million loss in the prior year period. Research and development expenses increased to $2.6 million from $0.7 million, while general and administrative expenses decreased to $0.9 million. As of June 30, 2026, NeOnc held approximately $2.0 million in cash and had an undrawn $10.0 million line of credit with a related party. The company also secured UAE IND approvals for its NEO100 and NEO212 programs and appointed Nasim Shomali to its Board of Directors. NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company developing treatments for central nervous system cancers.